Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06211595
Other study ID # DragonFire-01
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 13, 2022
Est. completion date November 30, 2024

Study information

Verified date January 2024
Source Hangzhou Valgen Medtech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single-center, single-arm clinical study. All patients were diagnosed with obstructive hypertrophic cardiomyopathy, and only subjects who met the instrument indications of this study were treated. After signing an informed consent form, subjects are enrolled and treated with the DragonFire Transcatheter Myocardial Ablation System. All subjects receive clinical follow-up immediately after the procedure, before discharge, 30 days after the procedure, 6 months after the procedure, and 12 months after the procedure.


Description:

This is a prospective, single-center, single-arm clinical study. All patients were diagnosed with obstructive hypertrophic cardiomyopathy, and only subjects who met the instrument indications of this study were treated. After signing an informed consent form, subjects are enrolled and treated with the DragonFire Transcatheter Myocardial Ablation System. The primary efficacy endpoint was the rate of major adverse events 30 days after surgery. The safety endpoints were the rate of immediate postoperative success and postoperative device success All subjects receive clinical follow-up immediately after the procedure, before discharge, 30 days after the procedure, 6 months after the procedure, and 12 months after the procedure.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date November 30, 2024
Est. primary completion date December 6, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years 2. Obstructive hypertrophic cardiomyopathy, peak LVOT pressure difference =50mmHg at rest or after excitation; 3. Obvious clinical symptoms, fatigue, shortness of breath, fatigue angina pectoris, syncope, etc., seriously affect the quality of life, and adequate drug treatment is not effective or can not tolerate drug side effects, after evaluation, transaortic interventional surgery can be performed; Exclusion Criteria: 1. Women who are pregnant, breastfeeding, or planning to become pregnant; 2. interventricular septum thickness =30mm; 3. non-hypertrophic obstructive cardiomyopathy; 4. Presence of cardiac neoplasms; 5. A history of interventricular septal resection or alcohol ablation, or Liwen surgery; 6. Combined with other heart diseases requiring surgical treatment; 7. Heart failure (after intensive anti-heart failure treatment, there are still symptoms of resting heart failure, such as left ventricular ejection fraction < 50%, N-terminal -B type natriuretic peptide precursor, NT-pro BNP=5000pg/ml, pulmonary edema, pleura or pericardial effusion, etc.); 8. Significant coronary lesions, or borderline lesions, requiring coronary revascularization due to mismatch between coronary perfusion and demand (QFR or FFR < 0.8), or coronary ischemic events within 30 days; 9. Bleeding diseases or clotting disorders; Or there is a contraindication of antithrombotic drug therapy; 10. estimated Glomerular Filtration Rate (eGFR) < 35ml/min; 11. Life expectancy was less than 12 months, and the investigator judged that the patient had poor compliance and could not complete the study as required; Or other circumstances in which the investigator considers the subject unsuitable for the study; 12. Subject is currently participating in an investigational drug or device study that has not completed its primary endpoint or that would clinically interfere with the endpoint of this study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
DragonFire Transcatheter Myocardial Radiofrequency Ablation System
The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography

Locations

Country Name City State
China The Second Xiangya Hospital, Central South University Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Hangzhou Valgen Medtech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of MAE Major adverse Event (MAE) is defined as any instrument-related or surgery-related complication, including death, emergency surgery, severe pericardial tamponade requiring pericardiocentesis or surgery, bleeding, surgery-related stroke, pacemaker implantation, and mechanically assisted circulation 30 days
Secondary Acute procedural success The device arrived at the intended treatment site for ablation, and was successfully withdrawn after ablation Immediately after procedure
Secondary Percentage of subjects with left ventricular outflow tract pressure (LVOTG) reduction of =50% or left ventricular outflow tract pressure (LVOTG) < 30mmHg Percentage of subjects with left ventricular outflow tract pressure (LVOTG) reduction of =50% or LVOTG< 30mmHg after the procedure 12 months
Secondary Incidence of device or device-related adverse events and device defects 12 months
Secondary Quality of life improvement Improvement in quality of life (QoL) , as measured by the Kansas City Cardiomyopathy Questionnaire,a scale of 0-100 with higher scores indicating better health 6 months, 12months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06023186 - Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
Completed NCT05726799 - Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
Active, not recruiting NCT03723655 - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Phase 2/Phase 3
Completed NCT04603521 - Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
Recruiting NCT06116968 - An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM Phase 3
Completed NCT03470545 - Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Phase 3
Recruiting NCT05879523 - A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy Phase 1
Not yet recruiting NCT06146660 - A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Recruiting NCT05771987 - Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. N/A
Active, not recruiting NCT05174416 - A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM Phase 3
Recruiting NCT06224621 - Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy N/A
Completed NCT01631006 - Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy N/A
Not yet recruiting NCT06368037 - Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy N/A
Recruiting NCT05489705 - A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
Completed NCT06354556 - Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects Phase 1
Completed NCT04783766 - Safety, Tolerability and Pharmacokinetics Study of CK-3773274 Phase 1